![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Rigel Pharmaceuticals Finalizes Pact with Eli Lilly for RIPK1 Inhibitor
Rigel Pharmaceuticals Finalizes Pact with Eli Lilly for RIPK1 Inhibitor
![team up](https://www.fdanews.com/ext/resources/test/Device_Images5/team-up-text.gif?t=1590011221&width=430)
April 8, 2021
Rigel Pharmaceuticals and Eli Lilly have finalized an agreement to jointly develop Rigel’s RIPK1 inhibitor, R552, for a variety of autoimmune and inflammatory diseases.
RIPK1 (receptor-interacting serine/threonine-protein kinase 1) is an enzyme that regulates immune cells and RIPK1 inhibitors are being investigated as potential oral treatments for a range of degenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease.
Under the agreement, Rigel received an upfront payment of $125 million, with the potential for an additional $330 million in milestone payments for noncentral nervous system (CNS) disease products, and $255 million in milestone payments for CNS disease products.
Upcoming Events
-
21Oct